Device Trial Radar · NCT05393180
CONVERGE Post-Approval Study (PAS)
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
53
Actual
Start
Apr 13, 2022
Primary completion
Feb 26, 2027
Study completion Nov 21, 2028
Sponsor
- Lead sponsor
- AtriCure, Inc.Public (ATRC)
- Sponsor type
- Industry
- First posted
- May 26, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Conditions
- Chronic Atrial Fibrillation
Interventions
Epicardial And Endocardial RF Ablation For The Treatment Of Symptomatic Long-standing Persistent AFDevice
Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. This will be done endocardially using an irrigated endocardial ablation catheter. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation. .
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from AF/AFL/AT >30 seconds through 12 months absent new or increased dose of class I/III AAD.Time frame: 1 year
- Primary Safety Endpoint, Incidence of defined Major Adverse EventsTime frame: 30-days post procedure
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
Sutter Bay Hospitals
San Francisco, California
Hartford Hospital
Hartford, Connecticut
Baycare Health Systems
Clearwater, Florida
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.